The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
Abstract
PURPOSE: Tamoxifen is an effective treatment for metastatic and primary breast cancer and is now being evaluated as a chemoprevention agent in healthy women. Any long-term effects on estrogen-sensitive tissues such as bone may have important therapeutic implications. METHODS: We measured bone mineral density (BMD) in the lumbar spine and hip using dual-energy x-ray absorptiometry (DXA) in premenopausal and postmenopausal healthy women who participated in our placebo-controlled tamoxifen chemoprevention of breast cancer trial. RESULTS: BMD data are now available from 179 women for this analysis. In premenopausal women, BMD decreased progressively in the lumbar spine (P < .001) and in the hip (P < .05) for women on tamoxifen, but not those on placebo. The mean annual loss in lumbar BMD per year over the 3-year study period in tamoxifen-treated compliant women who remained premenopausal throughout the study period was 1.44% (1.88% calculated on an intent-to-treat basis) compared with a small gain of 0.24% per annum for women on placebo (P < .001). Tamoxifen had the opposite effect in postmenopausal women. The mean annual increase in BMD for women on tamoxifen was 1.17% in the spine (P < .005) and 1.71% in the hip (P < .001) compared with a noninsignificant loss for women on placebo. CONCLUSION: These results indicate that tamoxifen treatment is associated with a significant loss of BMD in premenopausal women, whereas it prevents bone loss in postmenopausal women. These adverse and beneficial effects of tamoxifen should be considered in the assessment of the therapeutic benefits for both the adjuvant treatment and the chemoprevention of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Evidence of Estrogen Receptors in Normal Human Osteoblast-Like Cells
Eriksen, E. F., Colvard, D. S., Berg, N. J., Graham, M. L., Mann, K. G., Spelsberg, T. C., & Riggs, B. L. (1988) · Science · doi:10.1126/science.3388021 · Cited by 1,229
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
(1991) · PubMed · Cited by 1,101
LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN
Lindsay, R., Aitken, J. M., Anderson, L. B., Hart, D. M., Macdonald, E. B., & Clarke, A. C. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92217-0 · Cited by 952
Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer
Early Breast Cancer Trialists' Collaborative Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198812293192601 · Cited by 933
Estrogen Binding, Receptor mRNA, and Biologic Response in Osteoblast-Like Osteosarcoma Cells
Komm, B. S., Terpening, C. M., Benz, D. J., Graeme, K. A., Gallegos, A., Korc, M., Greene, G. L., O'Malley, B. W., & Haussler, M. R. (1988) · Science · doi:10.1126/science.3164526 · Cited by 812
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Parfitt, A. M. (1984) · Calcified Tissue International · doi:10.1007/bf02406145 · Cited by 441
Gottardis, M. M., & Jordan, V. C. (1987) · PubMed · Cited by 378
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
Jordan, V. C. (1976) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(76)90030-x · Cited by 371
Powles, T., Hardy, Jr., Ashley, S., Farrington, G., Cosgrove, D., Davey, J., Dowsett, M., McKinna, J., Nash, A., Sinnett, H., et al. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.235 · Cited by 246
Self-citationTamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats
Turner, R. T., Wakley, G. K., Hannon, K. S., & Bell, N. H. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020513 · Cited by 242
TURNER, R. T., WAKLEY, G. K., HANNON, K. S., & BELL, N. H. (1988) · Endocrinology · doi:10.1210/endo-122-3-1146 · Cited by 224
TAMOXIFEN AND CONTRALATERAL BREAST CANCER
Cuzick, J., & Baum, M. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90338-1 · Cited by 216
Effects of Tamoxifen on Spinal Bone Density in Women With Breast Cancer
Turken, S., Siris, E., Seldin, D., Flaster, E., Hyman, G., & Lindsay, R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1086 · Cited by 194
Estrogen and Antiestrogen Action in Reproductive Tissues and Tumors
KATZENELLENBOGEN, B. S., BHAKOO, H. S., FERGUSON, E. R., LAN, N. C., TATEE, T., TSAI, T.-L. S., & KATZENELLENBOGEN, J. A. (1979) · Proceedings of the 1978 Laurentian Hormone Conference · doi:10.1016/b978-0-12-571135-7.50010-2 · Cited by 190
Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer
Taube, T., Elomaa, I., Blomqvist, C., Beneton, M. N. C., & Kanis, J. A. (1994) · Bone · doi:10.1016/8756-3282(94)90703-x · Cited by 171
Self-citationLove, R. R., Mazess, R. B., Tormey, D. C., Barden, H. S., Newcomb, P. A., & Jordan, V. C. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01811242 · Cited by 156
The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
Powles, T. J., Jones, A. L., Ashley, S. E., O'Brien, M. E. R., Tidy, V. A., Treleavan, J., Cosgrove, D. O., Nash, A. G., Sacks, N., Baum, M., et al. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689678 · Cited by 155
Self-citationRecovery of bone density in women who stop using medroxyprogesterone acetate
Cundy, T., Cornish, J., Evans, M. C., Roberts, H., & Reid, I. R. (1994) · BMJ · doi:10.1136/bmj.308.6923.247 · Cited by 152
Suppression of Mouse Mammary Tumorigenesis by Long-Term Tamoxifen Therapy
Jordan, V. C., Lababidi, M. K., & Langan-Fahey, S. M. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.7.492 · Cited by 134
Ward, R. L., Morgan, G., Dalley, D. N., & Kelly, P. J. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80220-6 · Cited by 130
Fisher, B., BROWN, A., Wolmark, N., REDMOND, C., Wickerham, D. L., WITTLIFF, J., DIMITROV, N., LEGAULT-POISSON, S., SCHIPPER, H., & PRAGER, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-5-649 · Cited by 120
The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats
Gallagher, A. C., Chambers, T. J., & Tobias, J. H. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243306 · Cited by 100
Migliaccio, S., Davis, V. L., Gibson, M. K., et al. (1992) · Endocrinology · doi:10.1210/endo.130.5.1572285 · Cited by 71
Bone mineral content of women receiving tamoxifen for mastalgia
Is, F., Caleffi, M. M., Rodin, A., Murby, B., & Fogelman, I. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.266 · Cited by 66
Antiestrogen and antiandrogen administration reduce bone mass in the rat
Feldmann, S., Minne, H. W., Parvizi, S., Pfeifer, R., Lempert, U. G., Bauss, F., & Ziegler, R. (1989) · Bone and Mineral · doi:10.1016/0169-6009(89)90081-0 · Cited by 52
Peto, R. (2008) · Hormone Research · doi:10.1159/000181336 · Cited by 40
Cited by
Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Metadata
- Authors
- Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A., & Ashley, S.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-01
- Volume
- 14
- Issue
- 1
- Pages
- 78-84
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127677509
- Cited by
- 646
- References
- 29
- FWCI
- 28.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.